At the turn of the 21st century, there was great excitement and anticipation of gene therapy as a ‘curative’ treatment for hemophilia A and B patients, particularly among those with moderate-to-severe forms of the disease. However, a recent forum…
Explore the latest updates on federal budget reconciliation, healthcare lawsuits, and state-level policy changes impacting bleeding disorders. Learn how NBDF is advocating for access, funding, and patient protections.Federal: …
An analysis of the My Life, Our Future genetic database found that people with severe hemophilia A who are Black or Hispanic had a higher risk of developing inhibitors. It also found that the risk of inhibitor development was…
Mayra Cantu, from Oswego,Il. I am a symptomatic hemophilia A carrier. I have three sons with severe Hemophilia A. The boys keep me on my toes. I have been involved in the bleeding disorders community for 20 years now. I’m looking forward to this new…
Stacy J. Pechter, MS, BSN, RN, is a hematology-oncology nurse and nursing informatics specialist with more than a decade of involvement in the bleeding disorder community. Living with a rare bleeding disorder, they bring both personal insight and…
Concizumab-mtci (Alhemo®) has received approval from the US Food and Drug Administration (FDA) as a once-daily prophylactic treatment for patients aged 12 years and older with hemophilia A or B without inhibitors.This new approval results…
The National Bleeding Disorders Foundation’s (NBDF) 77th Annual Bleeding Disorders Conference (BDC) is finally here. We like to think of this as a family reunion – whether you’re new to the community or have been attending for years, you’ll be…